Understanding Non-Progressive Congenital Ataxia (NPCA) in Kids Aged 5–8
Official title: Non-progressive Congenital Ataxia - Advancing Diagnosis to Enhance Chances for Targeted Therapy
Run by Vastra Gotaland Region · NCT07421219 · Data updated 2026-11-12
This European observational study tests how NPCA, a form of ataxic cerebral palsy, presents over time in children aged 5–8 and what family and quality-of-life factors look like.
Quick facts
| Study type | Observational |
|---|---|
| Ages | 5 Years to 8 Years |
| Sex | All |
| Enrollment | 50 (estimated) |
| Sponsor | Vastra Gotaland Region Government |
| Locations | 7 sites (Leuven and 6 other locations) |
| Status | Recruiting |
| Started | May 15, 2026 |
| Main results expected | June 2027 |
| Study ends | December 31, 2027 |
| Registry record updated | August 27, 2026 |
| Trial ID | NCT07421219 on ClinicalTrials.gov |
Is this trial a fit for you?
✓Likely a good fit
Children aged 5–8 years with a confirmed NPCA/ataxic CP diagnosis (SCPE criteria).
✕Probably not a fit
Children without NPCA or outside the 5–8 age range are unlikely to benefit.
A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.
What this trial studies
ARTEMIS is a multinational observational study enrolling children 5 to 8 with NPCA/ataxic CP to map clinical features, brain MRI patterns, and genetic findings. It collects retrospective neonatal data and current assessments to describe developmental trajectories and impairment profiles. The study also examines quality of life for patients and the burden on families, along with typical healthcare pathways. Data come from centers in France, Belgium, Denmark, Germany, Greece, Norway, Hungary, and Sweden. No interventions are being tested; the goal is to better understand the condition and its diverse presentations.
Why it matters
Potential benefit: Improved understanding of NPCA could lead to better diagnosis, management, and support for affected children and their families.
How similar studies have gone: Previous observational efforts have described NPCA features, but this project aims to integrate clinical, imaging, and genetic data across multiple centers.
Who can join: the full rules
Show full inclusion / exclusion criteria
Inclusion Criteria: • male or female children * confirmed diagnosis of NPCA/Ataxic CP (SCPE definition) * aged ≥ 5 years and ≤ 8 years at time of data collection * written informed consent of at least one parent or legal representative in accordance to country regulations, and verbal assent of the child when possible Exclusion Criteria: Children with all other diagnoses of movement disorders or other CP subtypes \-
Where it's running
-
University Hospital Tübingen
Tübingen, Germany Recruiting -
Queen Silvia Children's Hospital at Sahlgrenska University Hospital
Gothenburg, Sweden Recruiting -
KU Leuven
Leuven, Belgium Not yet recruiting -
Aarhus University Hospital
Aarhus, Denmark Not yet recruiting -
Toulouse University Hospital
Toulouse, France Not yet recruiting -
IASO Children's Hospital
Athens, Greece Not yet recruiting
Show 1 more location
-
Vestfold Hospital Trust
Tønsberg, Norway Not yet recruiting
Study contacts
- Study coordinator: Kate Himmelmann, MD PhD
- Email: kate.himmelmann@vgregion.se
- Phone: +46 702225589, +46 722039472
Similar studies
Other studies for the same condition or treatment. Recruiting studies are listed first.
-
VOJTA technique for children with ataxic cerebral palsy
This trial will test whether VOJTA therapy helps children aged 2–6 with ataxic cerebral palsy improve muscle tone, balance, and gross motor skills.
-
Registry for patients with rare diseases
This study is creating a central registry for people with rare diseases to help connect them with researchers and improve treatments.
How to take part
- Review the eligibility criteria above with your treating physician.
- Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
- Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.